ID   UPMD-1
AC   CVCL_C297
SY   UPMD1; Uveal Primary Melanoma with Disomy-3 1
DR   cancercelllines; CVCL_C297
DR   Cosmic; 1628403
DR   DepMap; ACH-002926
DR   Wikidata; Q54991702
RX   PubMed=19212147;
RX   PubMed=22236444;
RX   PubMed=23849826;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 100 hours (PubMed=19212147).
CC   Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=22236444).
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): PubMed=22236444
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 11,13
ST   D16S539: 12
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   FGA: 21,22
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 14,15
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 16
//
RX   PubMed=19212147; DOI=10.1159/000201566;
RA   Nareyeck G., Zeschnigk M., Bornfeld N., Anastassiou G.;
RT   "Novel cell lines derived by long-term culture of primary uveal
RT   melanomas.";
RL   Ophthalmologica 223:196-201(2009).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by gefitinib and cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//